ZENAS BIOPHARMA, INC. (ZBIO)
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (92%) **Content type:** Clinical